BOSTON--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the year ended December 31, 2014, and also commented on corporate accomplishments and plans.
“COMMAND enrollment remains on track and we continue to anticipate conducting the pre-specified interim analysis in the second quarter of 2015,” said Robert Forrester, President and Chief Executive Officer of Verastem.
Help employers find you! Check out all the jobs and post your resume.
